Effect of intravenous dose on hydralazine kinetics after administration

Authors:

Abstract
Six male hypertensive patients, 3 rapid and 3 slow acetylators, each received 4 different I.v. hydralazine doses by constant infusion over 100 s. Two-4 days elapsed between doses. Plasma or whole-blood hydralazine concentrations were measured by HPLC [high performance liquid chromatography] after each dose. There was no influence of acetylator phenotype on hydralazine kinetics after i.v. dosing. There also was no consistent effect of dose size on hydralazine clearance or volume of distribution at doses up to 0.45 mg (2.3 .mu.mol/kg). One subject, who received doses up to 0.6 mg/kg (3.05 .mu.mol), had an apparent decrease in clearance at the higher doses. These findings are consistent with the fact that hydralazine is converted intravascularly to hydralazine pyruvic acid hydrazone and the fact that potentially saturable hepatic metabolic pathways play only a modest role in systemic clearance.